Get the Stockscreener App
59.92
7.72%
-5.01
After Hours:
59.03
-0.89
-1.49%
Nektar Therapeutics stock is traded at $59.92, with a volume of 954.04K.
It is down -7.72% in the last 24 hours and down -1.04% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$64.93
Open:
$62.4
24h Volume:
954.04K
Relative Volume:
0.98
Market Cap:
$1.14B
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-41.04
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-4.24%
1M Performance:
-1.04%
6M Performance:
+7,868%
1Y Performance:
+4,772%
1-Day Range:
$57.33
$63.99
1-Week Range:
$57.33
$66.92
52-Week Range:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
59.92 | 1.23B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Is Nektar Therapeutics trending in predictive chart modelsJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Is Nektar Therapeutics stock a good choice for value investorsMarket Sentiment Report & Weekly Setup with High ROI Potential - newser.com
Why Nektar Therapeutics stock remains on buy listsWeekly Risk Summary & Fast Exit/Entry Strategy Plans - newser.com
Why retail investors pile into Nektar Therapeutics stockOil Prices & Verified Swing Trading Watchlist - newser.com
Pattern recognition hints at Nektar Therapeutics upsideGlobal Markets & Proven Capital Preservation Tips - newser.com
Published on: 2025-11-03 04:48:43 - newser.com
Why Nektar Therapeutics stock remains undervaluedJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionPortfolio Gains Summary & Community Consensus Picks - newser.com
Can Nektar Therapeutics (ITH0) stock sustain free cash flow2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
What margin trends mean for Nektar Therapeutics stockJuly 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Using economic indicators to assess Nektar Therapeutics potential2025 Year in Review & Daily Momentum Trading Reports - newser.com
Moody Aldrich Partners LLC Invests $1.17 Million in Nektar Therapeutics $NKTR - MarketBeat
Will Nektar Therapeutics continue its uptrend2025 Analyst Calls & AI Driven Price Predictions - newser.com
Nektar Therapeutics (NKTR): Valuation Reset as REZOLVE-AD Phase 2b Data and Analyst Optimism Drive Investor Interest - simplywall.st
Is Nektar Therapeutics (ITH0) stock undervalued at current priceQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 1-Year HighShould You Buy? - MarketBeat
Is Nektar Therapeutics (ITH0) stock a top dividend aristocrat candidateJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Is Up 8.0% After Late-Breaking Phase 2b Rezpegaldesleukin Data Announcement - Sahm
Nektar Therapeutics stock hits 52-week high at 65.97 USD - Investing.com
Best data tools to analyze Nektar Therapeutics stock2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Nektar Therapeutics (NKTR): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Can volume confirm reversal in Nektar TherapeuticsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PR Newswire
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Nektar Therapeutics $NKTR Holdings Trimmed by Deuterium Capital Management LLC - MarketBeat
Can Nektar Therapeutics stock resist market sell offsJuly 2025 Movers & Weekly High Return Opportunities - newser.com
Nektar Therapeutics (NKTR) to Release Earnings on Thursday - MarketBeat
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):